BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31611031)

  • 1. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid.
    Eshraghian A; Nikeghbalian S; Geramizadeh B; Kazemi K; Shamsaeefar A; Malek-Hosseini SA
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):572-578. PubMed ID: 31611031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of whole blood copper, zinc, calcium, magnesium, and iron with non-alcoholic fatty liver disease in overweight and obese children.
    Huang Z; Luo M; Dai W; Yao Z; Ouyang S; Xu N; Zhou H; Li X; Zhong Y; Luo J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 49(3):426-434. PubMed ID: 38970517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.
    Qureshi K; Abrams GA
    Clin Obes; 2016 Apr; 6(2):117-23. PubMed ID: 26856683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
    Fernández Rodríguez CM; Aller R; Gutiérrez García ML; Ampuero J; Gómez-Camarero J; Martín-Mateos RMª; Burgos-Santamaría D; Rosales JM; Aspichueta P; Buque X; Latorre M; Andrade RJ; Hernández-Guerra M; Romero-Gómez M
    Rev Esp Enferm Dig; 2019 Apr; 111(4):264-269. PubMed ID: 30810330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
    Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
    Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
    Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
    Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher serum uric acid to HDL-cholesterol ratio is associated with onset of non-alcoholic fatty liver disease in a non-obese Chinese population with normal blood lipid levels.
    Zhu W; Liang A; Shi P; Yuan S; Zhu Y; Fu J; Zheng T; Wen Z; Wu X
    BMC Gastroenterol; 2022 Apr; 22(1):196. PubMed ID: 35448944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A cross-sectional study on the prevalence rate and influencing factors of non-alcoholic fatty liver disease in overweight/obese children].
    Dai W; Yao ZZ; Ou-Yang SS; Xu NA; Zhou HX; Li XW; Zhong Y; Luo JY
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 May; 25(5):448-456. PubMed ID: 37272169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver in Lean Individuals: Clinicobiochemical Correlates of Histopathology in 157 Liver Biopsies from Healthy Liver Donors.
    Choudhary NS; Saraf N; Saigal S; Duseja A; Gautam D; Rastogi A; Bhangui P; Thiagrajan S; Soin AS
    J Clin Exp Hepatol; 2021; 11(5):544-549. PubMed ID: 34511814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
    Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?
    Kumar R; Rastogi A; Sharma MK; Bhatia V; Garg H; Bihari C; Sarin SK
    Indian J Endocrinol Metab; 2013 Jul; 17(4):665-71. PubMed ID: 23961483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.